Hypothyroidism is a ubiquitous condition. According to the National Board of Health and Welfare, thyroid-hormone replacement was prescribed to approximately 370,000 individuals in Sweden during 2010.
the sample were taken at the wrong time, another dropped out after 3 days due to intolerable fatigue.
Individual fT3/fT4 and TSH-levels are shown in Figures 1 and 2, respectively. A statistically significant systematic change in fT3/fT4-levels (p<0.001) was observed. Median fT3/fT4 increased from 0.23 (0.17-0.32) to 0.28 (0.22-0.42) pmol/l. Similarly, there was a rise in TSH-levels (p<0.001) across the observation points. Median TSH increased from 0.6 (0.03-3.04) to 4.64 (0.58-7.52) mU/l during the study. Additionally, a statistically significant increase in T3/T4-levels was seen between days 3 and 6 (p=0.05). TSH-levels increased significantly between baseline and day 3 (p=0.004) as well as between days 3 and 6 (p=0.004).
Discussion
In the treatment of hypothyroidism seen in clinical practice, levothyroxine is given in monotherapy and adequate dosing is considered when plasma TSH levels normalise. Despite this, many patients have recalcitrant symptoms of hypothyroidism. Several studies have found that the ratio of T3/T4 differ and are consistently lower with levothyroxine substitution compared with healthy subjects. [5] [6] [7] [8] The ratio of those who received replacement therapy with the intention to normalise or even to attain subnormal levels of serum TSH was studied. The ratio of fT3/fT4 was lowest in the group with subnormal TSH, although the difference was not significant. 8 It is known that TSH is important for the conversion to fT3 although the clinical significance of this is not completely understood. In the present study we demonstrated that temporary discontinuation of oral levothyroxine results in increased plasma TSH levels and fT3 to fT4 ratios. Within 3 days after discontinuation of levothyroxine, a significant trend was noted. Our results suggest that there is a direct correlation between TSH levels and the conversion of fT4 to fT3. Since treatment of hypothyroidism lowers TSH, it may be an explanation for why patients with replacement therapy have a fT3/fT4 ratio that is lower than healthy controls.
As some patients have remaining symptoms and relatively lower levels of T3, levothyroxine treatment in monotherapy has frequently been questioned. Investigations mimicking healthy subjects with T4 and T3 in combination have been tested in several studies but have produced ambiguous results. A meta-analysis including 11 studies and 1,200 patients found no advantage of T3 and T4 in combination regarding terms of quality of life (QOL) and residual hypothyroidism symptoms. 9 However, in a more recent study by Nygaard et al., which differs from previous studies in that a higher dose of T3 in combination with T4 was given, benefits of combined therapy in terms of QOL, depression and anxiety were shown. The T3/T4-ratio in that study was even higher than in healthy controls. 10 This indicates that it may be relevant to raise the levels of T3.
Thus far, only combination therapies using T4 and T3 have been attempted. If a treatment could provide levothyroxine in adequate quantities without a simultaneous downregulation of TSH levels, it may be possible to raise that ratio to better reflect the hormonal patterns of healthy subjects. Hypothetically, an oral replacement regimen scheduled every other or every third day may be beneficial. Our results justify further and more extensive studies concerning such regimens. Hopefully, it would also provide fewer of the side effects that occur with oral T3. In summary, this study showed that short-term withdrawal of levothyroxine was associated with higher plasma TSH levels and an increased fT3 to fT4 ratio, which more closely resembled ones found in healthy subjects. The study was too small to make measurements on symptoms and quality of lives scores. ■
